CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Mizuho Reiterates Outperform Rating on Arcutis Biotherapeutics Inc. (ARQT)
August 16, 2024 2:59 PM EDTMizuho analyst Uy Ear reiterated an Outperform rating and $19.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT)
The analyst comments "For the week ending 08/09/2024, the Zoryve franchise grew 10.5% (vs +4.2% in the prior week) for TRxs and 6.3% (vs +12.4% in the prior week) for... More
